May, 2024
May 2024
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Myeloma Paper of the Day, May 16th, suggested by Robert Orlowski
May 16, 2024, 15:09

Myeloma Paper of the Day, May 16th, suggested by Robert Orlowski

Robert Orlowski shared on X:

Myeloma Paper of the Day: DESCAR-T registry of French patients getting idecabtagene vicleucel CAR T for relapsed/refractory myeloma finds best ORR and ≥CR rates were 88% and 47%, respectively; median PFS was 12.5 months, and median OS was 20.8 months.”

Source: Robert Orlowski/X

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry

Authors: B. Ferment, J. Lambert, D. Caillot, I. Lafon, L. Karlin, A. Lazareth, C. Touzeau, X. Leleu, N. Moya, S. Harel, A. Perrot, P. Bories, L. Vincent, S. Lamure, M. Mohty, F. Malard, S. Manier, I. Yakoub-Agha, J.-M. Schiano De Colella, G. Brisou, A. Talbot, O. Decaux, R. Houot, S. Le Gouill, N. Bigot, T. Facon, J. Corre, P. Moreau, B. Arnulf

Myeloma Paper of the Day

Other insights by Robert Orlowski on OncoDaily.

Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.